Details for New Drug Application (NDA): 209241
✉ Email this page to a colleague
NDA 209241 describes INGREZZA, which is a drug marketed by Neurocrine and is included in two NDAs. It is available from one supplier. There are twenty-two patents protecting this drug. Additional details are available on the INGREZZA profile page.
The generic ingredient in INGREZZA is valbenazine tosylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
The generic ingredient in INGREZZA is valbenazine tosylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the valbenazine tosylate profile page.
Summary for 209241
| Tradename: | INGREZZA |
| Applicant: | Neurocrine |
| Ingredient: | valbenazine tosylate |
| Patents: | 22 |
Pharmacology for NDA: 209241
| Mechanism of Action | Vesicular Monoamine Transporter 2 Inhibitors |
Suppliers and Packaging for NDA: 209241
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241 | NDA | Neurocrine Biosciences, Inc. | 70370-1060 | 70370-1060-1 | 30 CAPSULE in 1 BOTTLE (70370-1060-1) |
| INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241 | NDA | Neurocrine Biosciences, Inc. | 70370-1080 | 70370-1080-1 | 30 CAPSULE in 1 BOTTLE (70370-1080-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 40MG BASE | ||||
| Approval Date: | Apr 11, 2017 | TE: | AB | RLD: | Yes | ||||
| Regulatory Exclusivity Expiration: | Aug 18, 2030 | ||||||||
| Regulatory Exclusivity Use: | FOR TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE | ||||||||
| Regulatory Exclusivity Expiration: | Aug 18, 2026 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF ADULTS WITH CHOREA ASSOCIATED WITH HUNTINGTON’S DISEASE | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Oct 28, 2036 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | A METHOD OF TREATING HUNTINGTON'S CHOREA | ||||||||
Complete Access Available with Subscription
